CRK Polyclonal Antibody, Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-2763R-Cy7 |
| Product Name | CRK Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Crk p38 /CrkII |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 1398 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | CRK; CRK isoform 2; CrkII; CRK isoform II; CRKII; p38; Proto oncogene C crk; v crk avian sarcoma virus CT10 oncogene homolog; v crk sarcoma virus CT10 oncogene homolog; v crk sarcoma virus CT10 oncogene homolog avian; Adapter molecule crk; Avian sarcoma virus CT10 v crk oncogene homolog. |
| Background | Crk p38 (CrkII) is an isoform of the protein Crk. CrkI and CrkII are produced from the same crk gene by alternative splicing. The two isoforms differ in their biological activities with CrkII having less transforming activity than CrkI.Crk p38 is a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. It has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Crk is believed to be a regulator of invasive responses because increased levels of the protein have been observed in multiple human cancers. In vivo studies have demonstrated that decreased levels of Crk remarkably inhibits tumor formation and its invasive growth. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is CRK Polyclonal Antibody, Cy7 Conjugated (bs-2763R-Cy7) validated for, and at what dilution?
bs-2763R-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does CRK Polyclonal Antibody, Cy7 Conjugated (bs-2763R-Cy7) react with?
Tested reactivity: Human. Predicted reactivity (expected from sequence homology but not yet tested): Mouse, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit.
How should bs-2763R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise CRK Polyclonal Antibody, Cy7 Conjugated (bs-2763R-Cy7)?
KLH conjugated synthetic peptide derived from human Crk p38 /CrkII
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-2763R-Cy7)?
Cy7 on bs-2763R-Cy7: excitation / emission 743nm/767nm.